Will $24B Orphan drug leader partner with this $7M Microcap?

Dear Reader, Since the Orphan Drug Act was passed in 1983, the global market for development of drugs used to treat rare diseases has skyrocketed.  At that time, drug therapies for such diseases were rarely developed.  Now this is a multibillion dollar market.  Orphan diseases were often overlooked by the pharmaceutical industry since there is very little financial incentive to treat illnesses which affect fewer than 200,000 people nationwide.  This includes ailments such as Cystic Fibrosis, Lou Gehrig ’s disease, Huntington’s disease, and Tourette’s Syndrome. Alexion Pharmaceuticals, a $24 Billion dollar Biopharma, has become the Orphan Drug Leader with over $1.1 Billion in sales last year.  When they find a drug with a leading science behind it, they go after it.  Savvy investors know just where to look to find the next big drug.  Court filings have revealed that Alexion has just received the winning bid on assets from this $7M microcap company, and Wall Street hasn’t caught on yet….until now. Regards, The Team at TRADDR.com   This is a PAID ADVERTISEMENT provided to customers of Schaeffer's Investment Research. Although we have sent you this email, Schaeffer's not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above. Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click here. DISCLAIMER: In accordance with Section 17(b) of the Securities Act of 1933, you are hereby advised that Schaeffer’s Investment Research, Inc. "Schaeffer’s" is receiving a fee of over $1000.00 in cash, from an independent third party as compensation for the distribution of this advertisement. Schaeffer’s has not determined if the statements and opinions of the advertiser are accurate, correct or truthful. The purpose of this advertisement, like any advertising, is to provide publicity for the advertising company, its products or services. You should not rely on the information presented; you should do independent research to form your own opinion and decision. Information contained in our disseminated emails does not constitute investment, legal or tax advice upon which you should rely. The purchase of high-risk securities may result in the loss of your entire investment. Advertisements received by you are not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the States or other jurisdictions in which the security is eligible for sale. Advertisements distributed through disseminated emails are not disclosure documents. If you are considering purchasing any securities of an advertised company, you should call your State Securities Administrator to determine if the security may be sold in your State. Many companies have information filed with State securities regulators who may be able to supply you with additional information. You also should read and review, if and to the extent available, any information concerning an advertised company available at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at http://‌www.‌sec.‌gov and the Financial Industry Regulatory Authority (the "FINRA") at http://‌www.‌FINRA.‌org. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud at http://‌www.‌sec.‌gov/‌consumer/‌cyberfr.‌htm, as well as related information published by the NASD on how to invest carefully. You are responsible for verifying all claims and conducting your own due diligence. You agree and acknowledge that any hyperlinks to the website of (1) an advertised company, (2) the party issuing or preparing the information for the advertised company, or (3) other information contained in our disseminated emails is provided only for your reference and convenience. We are not responsible for the accuracy or reliability of these external sites, nor are we responsible for the content, advertising, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated email or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on us, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. You also acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser. You acknowledge that you will consult with your own advisers regarding any decisions as to any advertised company. Schaeffer's Investment Research 5151 Pfeiffer Road, Suite 250 Cincinnati, Ohio 45242